Dark

RNLX
Renalytix plc
stock NASDAQ

Inactive

Oct 7, 2024

0.2071USD+5.663%(+0.0111)934,496

Pre-market

0.00USD-100.000%(-0.20)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 27, 2022

07:00AM EST Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix or the Company) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. GlobeNewswire Inc

Jan 18, 2022

06:11AM EST HC Wainwright & Co. Initiates Coverage On Renalytix with Buy Rating, Announces Price Target of $30 Benzinga

Jan 11, 2022

08:26AM EST Renalytix Highlights Study Results For Co.'s KidneyIntelX Published In 'The American Journal Of Nephrology,' Showed 'KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment...' Benzinga

08:15AM EST Renalytix (NASDAQ: RNLX)(LSE: RENX) announced the publication of positive study results for KidneyIntelXas a risk monitoring tool to assess impact and response to novel treatments for patients with diabetes and chronic kidney disease (CKD) at increased risk for cardiovascular events. These peer-reviewed findings were published in The American Journal of Nephrology. GlobeNewswire Inc

Jan 10, 2022

07:00AM EST Singing River Health System and Renalytix Join Forces to Improve GlobeNewswire Inc

Jan 7, 2022

07:04AM EST Renalytix Appoints Jean Casner As Chief Human Resources Officer RTTNews

Jan 5, 2022

07:00AM EST Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the Company will be presenting at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference. GlobeNewswire Inc

Jan 4, 2022

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2022 Benzinga

07:18AM EST American Diabetes Association And Renalytix Partner To Prioritize Kidney Health In Type 2 Diabetes Population Benzinga

07:00AM EST American Diabetes Association and Renalytix Partner to Prioritize GlobeNewswire Inc

06:55AM EST BTIG Initiates Coverage On Renalytix with Buy Rating, Announces Price Target of $24 Benzinga

Dec 7, 2021

08:26AM EST The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck's HIV Program, Decision Day For Dar Benzinga

07:21AM EST Renalytix AI Q2 Sales $500.00K Up From $400.00K YoY Benzinga

07:16AM EST Renalytix Q1 Net Loss Attributable To Ordinary Shareholders $10.1 Mln Vs $7.2 Mln Last Year RTTNews

07:02AM EST Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended September 30, 2021. GlobeNewswire Inc

03:57AM EST Earnings Scheduled For December 7, 2021 Benzinga

Dec 2, 2021

07:00AM EST Renalytix to Report First Quarter Fiscal Year 2022 Financial GlobeNewswire Inc

Nov 10, 2021

07:00AM EST Renalytix Convenes Expert Panel at VA Healthcare Summit GlobeNewswire Inc

Nov 9, 2021

07:00AM EST St. Josephs Health and Renalytix Partner to GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO Benzinga

12:11PM EDT Renalytix Reports FY21 Sales $1.5M Benzinga

12:11PM EDT Earnings Scheduled For October 21, 2021 Benzinga

07:00AM EDT Renalytix plc (NASDAQ: RNLX),(LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care,announces its results for the twelve months ended 30 June 2021. GlobeNewswire Inc

Oct 8, 2021

07:00AM EDT Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 GlobeNewswire Inc

Oct 7, 2021

07:00AM EDT Renalytix Launching KidneyIntelX in Veterans Health Administration GlobeNewswire Inc

Sep 14, 2021

07:00AM EDT Mount Sinai Initiates System-wide Scale-Up of Renalytix GlobeNewswire Inc

Sep 3, 2021

07:00AM EDT Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference. GlobeNewswire Inc

Aug 30, 2021

07:19AM EDT Renalytix Appoints Daniel Levangie To Board RTTNews

07:00AM EDT Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J. Levangie to the Companys board of directors. Mr. Levangie is also appointed as a member of the Companys remuneration committee. GlobeNewswire Inc

Aug 26, 2021

07:00AM EDT Payer Budget Impact Analysis Projects Significant Savings from GlobeNewswire Inc

Aug 18, 2021

10:45AM EDT Mid-Morning Market Update: Markets Mixed; Target Reports Upbeat Profit Benzinga

Jul 28, 2021

07:00AM EDT Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Ann E. Berman to its board of directors. She will chair the boards audit committee and serve as member of the nomination committee. GlobeNewswire Inc

Jul 26, 2021

07:00AM EDT Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the company will be presenting at the upcoming 41st Annual Canaccord Genuity Virtual Global Growth Conference. GlobeNewswire Inc

Jul 22, 2021

07:00AM EDT Renalytix Appoints Joseph Hutson Vice President of Global Quality GlobeNewswire Inc

Jul 2, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 2, 2021 Benzinga

07:15AM EDT Berenberg Initiates Coverage On Renalytix with Buy Rating, Announces Price Target of $38 Benzinga

Jun 28, 2021

07:00AM EDT KidneyIntelX Enables Monitoring of SGLT2 GlobeNewswire Inc

Jun 15, 2021

07:17AM EDT Renalytix AI Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $619.00K Beat $610.00K Estimate Benzinga

07:00AM EDT Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today reported financial results for the quarter and nine months ended March 31, 2021. GlobeNewswire Inc

04:00AM EDT Earnings Scheduled For June 15, 2021 Benzinga

Jun 10, 2021

08:00AM EDT Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15, 2021, before market open. The Company will host a corresponding conference call and live webcast at 8:30 a.m. (EDT) / 1:30 p.m. (BST) to discuss the results and provide a corporate update. GlobeNewswire Inc

Jun 7, 2021

07:00AM EDT Leadership Additions Announced to Support Expanding US Government GlobeNewswire Inc

Jun 3, 2021

07:00AM EDT Utility Study Indicates KidneyIntelX Risk Assessment can Address GlobeNewswire Inc

Jun 2, 2021

11:41AM EDT Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under The COVID-19 Interim Order RTTNews

11:36AM EDT Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order. BZ NOTE: Kantaro Is A Joint Venture Between Mount Sinai Health System, RenalytixAI And Bio-Techne Benzinga

11:35AM EDT Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada PR Newswire

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 19, 2021

07:00AM EDT Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine announced a partnership to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. GlobeNewswire Inc

May 4, 2021

02:21PM EDT Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's PR Newswire

Apr 27, 2021

07:41AM EDT The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout Benzinga

Apr 22, 2021

02:40PM EDT Mid-Afternoon Market Update: Dow Falls 300 Points; Teradata Shares Spike Higher Benzinga

12:20PM EDT Mid-Day Market Update: Qualtrics International Jumps After Q1 Results; Evolus Shares Slide Benzinga

10:26AM EDT Renalytix AI plc (RNLX) shares are rising on Thursday morning trade as the company got a 10-year contract from the U.S. General Services Administration to provide KidneyIntelX early-stage kidney disease bio-prognostic testing services. RTTNews

10:18AM EDT Mid-Morning Market Update: Markets Down; AT&T Tops Q1 Views Benzinga

08:17AM EDT Benzinga Pro's Top 5 Stocks To Watch For Thursday, Apr. 22, 2021: T, TDC, XM, RNLX, GRNQ Benzinga

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

07:58AM EDT Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services Benzinga

07:22AM EDT U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing Benzinga

07:00AM EDT U.S. General Services Administration Grants 10-Year Governmentwide GlobeNewswire Inc

Apr 20, 2021

07:00AM EDT KidneyIntelX Demonstrates Performance and Informs Treatment GlobeNewswire Inc

Apr 14, 2021

07:03AM EDT Renalytix AI Reports Exclusive Option Deal With Joslin Diabetes Center For Patent Filings On Certain Added Novel Biomarkers In Kidney Disease For Development, Deployment In KidneyIntelX In Vitro Prognostic Platform, No Terms Disclosed Benzinga

07:00AM EDT Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX in vitro prognostic platform. GlobeNewswire Inc

Apr 8, 2021

07:00AM EDT Clinical Utility Study Demonstrates Primary Care Physicians Highly GlobeNewswire Inc

Apr 5, 2021

07:11AM EDT Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure Benzinga

07:00AM EDT Multi-Center Study Finds KidneyIntelX 72% More Effective Than GlobeNewswire Inc

Mar 16, 2021

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 15, 2021

07:00AM EDT Update on Finalization of MCIT Rule to Provide National Medicare GlobeNewswire Inc

Mar 12, 2021

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

Mar 11, 2021

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

Mar 10, 2021

10:32AM EST Innovative Companies for 2021 and Ranked First in the Joint Ventures Category PR Newswire

Mar 4, 2021

01:00PM EST Renalytix AI plcIssue of Shares Under the 2020 GlobeNewswire Inc

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

Mar 3, 2021

05:20AM EST COVID-19 Convalescent Plasma Study Shows No Benefit, US NIH Stops Trial Benzinga

Mar 2, 2021

07:28AM EST Renalytix AI Q2 EPS $(0.12), Sales $400.00K Benzinga

07:00AM EST Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (RenalytixAI or the Company), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter and six months ended December 31, 2020. GlobeNewswire Inc

03:40AM EST Earnings Scheduled For March 2, 2021 Benzinga

Feb 24, 2021

08:00AM EST Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, and the University of Utah, one of the top research institutions in the United States, today announced a partnership to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease. GlobeNewswire Inc

Feb 23, 2021

02:00AM EST RenalytixAI to announce Financial Results for six and three months GlobeNewswire Inc

Feb 10, 2021

11:34AM EST Kantaro Biosciences Joint Venture With Mount Sinai, RenalytixAI And Manufacturing Partner Bio-Techne Report FDA Added COVID-SeroKlir To Emergency Use Authorization For 'use of convalescent plasma for treating COVID-19 in hospitalized patients' Benzinga

11:32AM EST FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised PR Newswire

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 8, 2021

07:35AM EST Bio-Techne And RenalytixAI Joint Venture Kantaro Biosciences Enters Marketing And Distribution Agreement With Atrys Health; Atrys To Offer Kantaro's SARS-CoV-2 IgG Antibody Test Kits In Select European And South American Countries Benzinga

07:31AM EST Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative PR Newswire

Feb 4, 2021

07:00AM EST American Society of Nephrology and Renalytix to Co-Host Virtual GlobeNewswire Inc

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 22, 2021

07:22AM EST The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 13, 2021

02:00AM EST Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide GlobeNewswire Inc

Jan 6, 2021

07:31AM EST The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping Benzinga

Jan 5, 2021

06:00AM EST Early Risk Identification at Core of Innovative Kidney Care GlobeNewswire Inc

Jan 4, 2021

08:05AM EST Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the company will be presenting at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference. GlobeNewswire Inc

Dec 2, 2020

08:04AM EST NKF and RenalytixAI Partner to Improve Management of Early Stage Kidney Disease PR Newswire

Nov 25, 2020

02:35PM EST Mid-Afternoon Market Update: Nasdaq Gains 50 Points; RenalytixAI Shares Spike Higher Benzinga

11:01AM EST Why These 3 Health Care Stocks Are Trading Higher Today Benzinga

07:48AM EST Kantaro Receives Emergency Use Authorization For RTTNews

07:37AM EST RenalytixAI Joint Venture Kantaro Biosciences Receives FDA Emergency Use Authorization ForIts COVID-SeroKlir Semi-Quantitative COVID-19 Antibody Test Kit; Kits Being MAnufactured Through Partnership With Bio-Techne Benzinga

07:36AM EST Kantaro Receives FDA Emergency Use Authorization For COVID-SeroKlir RTTNews

07:35AM EST The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga

07:30AM EST Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies PR Newswire

07:00AM EST Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended September 30, 2020. GlobeNewswire Inc

Nov 13, 2020

02:00AM EST Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. GlobeNewswire Inc

Nov 6, 2020

07:00AM EST Renalytix AI plc (RenalytixAI GlobeNewswire Inc

Nov 2, 2020

10:30AM EST Posting of Annual Report & Accounts and Notice of AGM GlobeNewswire Inc

Oct 28, 2020

07:31AM EDT EKF and Kantaro Partner to Market Quantitative COVID-19 Antibody Testing in the PR Newswire

Oct 27, 2020

04:18AM EDT Earnings Scheduled For October 27, 2020 Benzinga

03:00AM EDT Renalytix AI plc (RenalytixAI GlobeNewswire Inc

Oct 26, 2020

07:59AM EDT Kantaro Biosciences Receives CE Marking For SARS-CoV-2 IgG RTTNews

07:47AM EDT Kantaro Gets CE Marking For COVID-SeroKlir And COVID-SeroIndex, Kantaro's Quantitative SARS-CoV-2 IgG Antibody Test Kits RTTNews

07:36AM EDT Kantaro Biosciences And Partner Bio-Techne Receive CE Mark For COVID-SeroKlir And COVID-SeroIndex SARS-CoV-2 IgG Antibody Test Kits Benzinga

07:31AM EDT CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex PR Newswire

Oct 16, 2020

07:01AM EDT RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and PR Newswire

Sep 22, 2020

07:00AM EDT RenalytixAI Receives California Commercial Laboratory Certification GlobeNewswire Inc

Sep 18, 2020

07:07AM EDT RenalytixAI Reports Commercial Launch Of KidneyIntelX Test Reporting Platform Within Mount Sinai Health System In NYC Benzinga

07:00AM EDT RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing GlobeNewswire Inc

Aug 26, 2020

07:00AM EDT RenalytixAI Files Submission Seeking U.S. FDA Clearance of GlobeNewswire Inc

Aug 21, 2020

05:36AM EDT RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease Benzinga

03:00AM EDT RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes GlobeNewswire Inc

Aug 12, 2020

09:41AM EDT Benzinga's Top Upgrades, Downgrades For August 12, 2020 Benzinga

Aug 11, 2020

08:00AM EDT Stifel Initiates Coverage On Renalytix AI with Buy Rating, Announces Price Target of $22 Benzinga

Aug 6, 2020

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Aug 3, 2020

08:23AM EDT KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients Benzinga

08:00AM EDT Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 GlobeNewswire Inc

Jul 27, 2020

08:01AM EDT RenalytixAI Announces Over Allotment Option Exercise Raises an GlobeNewswire Inc

Jul 21, 2020

03:57PM EDT RenalytixAI Announces Closing of Global Offering and Resulting GlobeNewswire Inc

Jul 17, 2020

11:18AM EDT Renalytix AI Shares Open For Trade At $13.90; IPO Priced At $13.50/Share Benzinga

11:06AM EDT Renalytix Shares Indicated $13.82 On 200K Shares Benzinga

10:20AM EDT Renalytix Shares Indicated To Open At $13.69 On 138K Shares Benzinga

09:52AM EDT Renalytix Indicated To Open At $14 On 51K Shares Benzinga

09:45AM EDT IPOs For July 17, 2020: Renalytix AI, Pandion Therapeutics, Deerfield Healthcare Technology, ALX Oncology And Berkeley Lights Benzinga

09:00AM EDT Renalytix Expected To Quote At 9:50 a.m. EDT; Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $13.50/Share Benzinga

Jul 16, 2020

11:38PM EDT Renalytix AI plc (LSE: RENX) (RenalytixAI or the Company), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the pricing of its global offering of an aggregate of 11,000,000 new ordinary shares (the Global Offering). GlobeNewswire Inc

Jul 13, 2020

08:58AM EDT RenalytixAI Announces Launch of Global Offering and Application to List on the PR Newswire

.dark-mode .WyTCrM{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .WyTCrM{ color: #333333; background-color: white; border: 2px solid #333333; }RNLXRenalytix plcstock NASDAQ

RNLX
Renalytix plc
stock NASDAQ